Accordingly, high levels of EphB4 expression in breast cancer cell lines was found to be often accompanied by low expression of its ligand, ephrin-B2, and this allows for signalling via ligand-independent pathways and evasion of EphB4’s tumour-suppressing effects [56,58]. The gene discussed is EFNB2; the disease is breast carcinoma.